London
· Delayed Price · Currency is GBP · Price in EUR Vivoryon Therapeutics Company Description
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines.
Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta.
The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease.
In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease.
Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.
| Country | Netherlands |
| Founded | 1997 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Frank Weber |
Contact Details
Address: Weinbergweg 22 Halle, 06120 Germany | |
| Phone | 49 345 555 9900 |
| Website | vivoryon.com |
Stock Details
| Ticker Symbol | 0R3M |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | NL00150002Q7 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Frank Weber | Chief Executive Officer |
| Anne Doering | Chief Financial Officer |
| Anne Doering | Head of Investor Relations |